1. Opening Hook
Ayurveda just went corporate—complete with EBITDA targets, insurance tie-ups, and international ambitions. Dr. Rohit Sane’s Madhavbaug wants to reverse diseasesandinvestor skepticism at once. With 320 clinics, 4 hospitals, and a Sonu Sood ad campaign, this Ayurvedic empire is mixing herbs with spreadsheets. The dream? One lakh patients, global clinics, and profit margins strong enough to give allopaths heartburn.Grab your herbal tea—this earnings call had more punch than a kashayam shot. 🌿📈
2. At a Glance
- Revenue ₹49.94 Cr (↑19.5% YoY):Ayurvedic growth—no modern medicine needed.
- EBITDA ₹8.62 Cr (↑49.6%):When therapies cure patientsandmargins.
- EBITDA Margin 17.3%:Discipline meets detox.
- PAT ₹4.84 Cr (↑28%):Doctor’s orders: healthy profits.
- Clinic Network:320+ centers, 255 franchise—because wellness scales better with partners.
- Hospital Beds:110, expanding to 350+—Ayurveda getting ICU ambitions.
- Madhavprash Units Sold:20,000/month—soon to hit 1 lakh. The new FMCG side hustle.
3. Management’s Key Commentary
“We aim to make disease reversal a scientific and accessible reality.”(Translation: Yoga mat meets business plan.)
“We’ll add 40–50 new clinics this year, and 70–80 next year.”(Translation: Franchising Ayurveda faster than chai startups.)
“Hospital capacity to rise to 1,000 beds in 3 years.”(Translation: Ayurvedic ICU dreams are getting real.)
“EBITDA margins above 15%, trending to 20% by FY28.”(Translation: Healing karma pays better every year.)
“International MoU signed in Malaysia with 70:30 profit share.”(Translation: Exporting Ayurveda—and hopefully, profits.) 😏
“Marketing at 14–15% of revenue featuring Sonu Sood.”(Translation: Celebrity detox meets DCF.)
“Aim: ₹250 Cr revenue by FY28, 1,000 clinics and 10 hospitals.”(Translation: The Patanjali playbook, MBA edition.)
“Cashless treatments across hospitals with TPA tie-ups.”(Translation: Ayurveda goes insurance-friendly. Even karma needs coverage.)
4. Numbers Decoded
| Metric | H1 FY25 | H1 FY26 | YoY Growth | Comment |
|---|---|---|---|---|
| Revenue | ₹41.8 Cr | ₹49.9 Cr | +19.5% | Pulse strong, BP under control. |
| EBITDA | ₹5.8 Cr | ₹8.6 Cr | +49.6% | Panchakarma magic, CFO-approved. |
| EBITDA Margin | 13.8% | 17.3% | +350 bps | Efficiency beats inflation. |
| PAT | ₹3.77 Cr | ₹4.84 Cr | +28% | Ayurveda for wealth. |
| PAT Margin | 9.0% | 9.7% | +66 bps | Doctor’s precision in profits. |
| Clinics | 320 | 370 (FY26E) | +16% | Herbal growth through franchising. |
| Hospitals | 4 | 10 (FY28 Target) | +150% | Ayurvedic beds on expansion spree. |
| Patients (H1FY26) | 65,000 | 1.3L (FY26E) | +58% | Wellness goes mass-market. |
Financial detox complete. Margins healthier than most patients.
5. Analyst Questions
Q:What’s the hospital expansion strategy?A:“Khopoli and Nagpur to hit 250+ beds; Vadodara next.”(Translation: Growth via more beds, fewer stress levels.)
Q:When’s main board listing?A:“In 6–7 months.”(Translation: SME graduation exam scheduled.)
Q:Status of ₹40L warrants?A:“NSE queries answered, approval pending.”(Translation: Bureaucracy – the only incurable disease.)
Q:Why Malaysia?A:“Global Ayurveda brand and patient referrals.”(Translation: Exporting Indian immunity to Southeast Asia.)
Q:Madhavprash ramp-up plan?A:“From 20k to 1L units per month in 2 years.”(Translation: Ayurveda meets Amul scale.)
Q:FY28 vision?A:“Revenue ₹280 Cr+, EBITDA 30–35%.”(Translation: Profits doing Surya
